We also apply our technical and legal expertise to obtain Supplementary Protection Certificates (SPCs) for our clients. We are well-versed in SPC legislation and case law, and regularly advise clients on this complex area of law.

Our contentious expertise extends from conducting offensive and defensive oppositions before the European Patent Office, often involving multiple parties and relating to cutting edge platform technologies, to representing clients in national litigation proceedings in the UK and Germany.

Our areas of technical specialism within pharmaceuticals and biotechnology include the clinical fields of cancer immunotherapy, microbiome therapy, cell and gene therapy and regenerative medicine. The technical background of our attorneys means we are well placed to advise on pharmaceutical products involving biologics, including therapeutic nucleotides and peptides, as well as new chemical entities. We also have significant experience of matters involving diagnostic assays, environmental testing for pathogens and agricultural and industrial biotechnology.

We believe the traditional one size fits all approach to client care is outdated. EIP Life is in an unrivalled position of being able to offer multi-qualified and multi-disciplinary teams to suit the specific needs of each client. Innovations in this sector are increasingly intersectional and, by bringing together life sciences expertise with EIP’s long established strengths in areas such as artificial intelligence and machine learning, our team provides an inter-disciplinary life sciences offering that keeps pace with such innovations.

Magnus Hallin(マグナス ハリン)

略歴

Magnus Hallin(マグナス　ハリン)